Professor

Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer

Monday, September 27, 2021 - 1:05pm

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the appointment of Lise Lund Kjems, MD, PhD as Chief Medical Officer.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the appointment of Lise Lund Kjems, MD, PhD as Chief Medical Officer.
  • We are thrilled to have Dr. Kjems join as our Chief Medical Officer, to lead and execute the clinical and medical activities for Cyclo Therapeutics.
  • Prior to that, she served as the Vice President, Clinical Development at Aldeyra Therapeutics and Executive Medical Director at Intarcia Therapeutics.
  • It is a privilege to be working with the team to lead the advancement of these important clinical programs, stated Dr. Kjems, Chief Medical Officer of Cyclo Therapeutics.

Vertosa Announces Appointment of Professor David Julian McClements as Founding Member of its Science Advisory Board

Monday, September 27, 2021 - 12:00pm

OAKLAND, Calif., Sept. 27, 2021 /PRNewswire/ -- Vertosa, a science-first cannabis company that creates the most effective and reliable active ingredients for infused products, today announced the appointment of Professor David Julian McClements as a Founding Member of the Vertosa Science Advisory Board.

Key Points: 
  • OAKLAND, Calif., Sept. 27, 2021 /PRNewswire/ -- Vertosa, a science-first cannabis company that creates the most effective and reliable active ingredients for infused products, today announced the appointment of Professor David Julian McClements as a Founding Member of the Vertosa Science Advisory Board.
  • A Distinguished Professor at the Department of Food Science at the University of Massachusetts, Amherst, Prof. McClements is the world's foremost scholar on food and agriculture science.
  • We are beyond excited to have Prof. McClements help Vertosa design the next generation of water-compatible cannabis ingredients and set industry standards."
  • "I'm impressed by Vertosa's commitment to science, precision and delivering consistent products to their customers," said Prof. McClements.

MINDCURE Launches "Desire Project" To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

Monday, September 27, 2021 - 8:30am

As part of MINDCURE's research and development, this research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder ("HSDD"), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue.

Key Points: 
  • As part of MINDCURE's research and development, this research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder ("HSDD"), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue.
  • "We know that sexual health contributes to overall wellbeing and that studies relating to HSDD suggest that female desire has deep roots in the mind.
  • "I'm very excited to lead our team and launch a clinical studyfor the treatment of female Hypoactive Sexual Desire Disorder," said Dr. Joel Raskin, Chief Medical Officer, MINDCURE.
  • This is an exciting opportunity to find a potentially more effective and better tolerated treatment for women affected by this disorder."

TISSIUM to Present Study Results at the 76th Annual Meeting of the American Society for Surgery of the Hand

Friday, September 24, 2021 - 11:25am

TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, has announced its research has been selected for presentation within the scientific program at the 76th Annual Meeting of the American Society for Surgery of the Hand.

Key Points: 
  • TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, has announced its research has been selected for presentation within the scientific program at the 76th Annual Meeting of the American Society for Surgery of the Hand.
  • The event is scheduled to be held virtually and in-person from September 30 October 2, 2021 in San Francisco, CA.
  • TISSIUM will present the latest research on its novel Sutureless Nerve Coaptation System in collaboration with surgeons from NYU Langone, Brigham & Womens Hospital, and SUNY Downstate Medical Center.
  • This novel material adheres strongly to tissue through mechanical interlocking, making it a highly unique tool that can act as an atraumatic means of tissue repair.

SYRACUSE UNIVERSITY AND THE MEAC SIGN ALLIANCE AGREEMENT

Thursday, September 23, 2021 - 8:18pm

SYRACUSE, NY, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Syracuse University and the Mid-Eastern Athletic Conference (MEAC) today announced they have signed a first-of-its-kind agreement, creating an alliance designed to connect institutions, students-athletes, staff and alumni.

Key Points: 
  • SYRACUSE, NY, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Syracuse University and the Mid-Eastern Athletic Conference (MEAC) today announced they have signed a first-of-its-kind agreement, creating an alliance designed to connect institutions, students-athletes, staff and alumni.
  • We are excited with the opportunities this alliance will create for MEAC institutions, Syracuse University, thousands of student-athletes, coaches and staff from MEAC institutions and Syracuse University.
  • First, I would like to thank John Wildhack, director of athletics at Syracuse University, for his vision and progressive leadership on this alliance, said Dr. Dennis Thomas, commissioner of the MEAC.
  • Located in Norfolk, Virginia, the MEAC is made up of eight outstanding historically black institutions across the Atlantic coastline: Coppin State University, Delaware State University, Howard University, University of Maryland Eastern Shore, Morgan State University, Norfolk State University, North Carolina Central University and South Carolina State University.

World Brand Lab Releases 'Asia's 500 Most Influential Brands of 2021'

Thursday, September 23, 2021 - 3:50pm

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- The "Asia Brand Summit" was held in Shanghai on September 23 by the World Brand Lab.

Key Points: 
  • NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- The "Asia Brand Summit" was held in Shanghai on September 23 by the World Brand Lab.
  • The "Asia's Most Influential Brands of 2021" list was released at the summit, which represents the 16th time that World Brand Lab has evaluated the influence of Asian brands.
  • The basic indicators used by World Brand Lab to evaluate the influence of Asian brands include market share, brand loyalty, and global leadership.
  • Haisen Ding, founder of World Executive Group and CEO of the World Brand Lab, believes that although Asian brands such as Toyota, Samsung, and Sony have enjoyed long-term global influence, there is still room for improvement in Asian brand leadership compared to American super brands.

Diadem Announces New Publication Reviewing How Post Translational Modifications of p53 Variants May Contribute to Development of Alzheimer's Disease

Thursday, September 23, 2021 - 7:00am

Increasing evidence suggests that certain conformational variants and post-translational modifications of p53, well known for its role in cancer, may significantly impact the development of AD.

Key Points: 
  • Increasing evidence suggests that certain conformational variants and post-translational modifications of p53, well known for its role in cancer, may significantly impact the development of AD.
  • This knowledge is already fueling creation of novel prognostic tests for AD and may lead to the development of new therapies to counter disease progression."
  • p53 is involved in the regulation of oxidative stress, which is implicated as one of the earliest events in AD.
  • Diadem is preparing for rapid commercialization of its initial Alzheimer's prognostic via a global launch in collaboration with strategic partners.

Affluent Medical : Financial results for the first half of 2021 and main clinical update.

Wednesday, September 22, 2021 - 6:56pm

During the first half of 2021, purchases consumed fell by 158 thousand compared to the first half of 2020.

Key Points: 
  • During the first half of 2021, purchases consumed fell by 158 thousand compared to the first half of 2020.
  • On 9 June 2021, Affluent Medical announced the success of its IPO on the regulated market of Euronext Paris.
  • Starting in 2018 he broadened his field of expertise by engaging in various entrepreneurial projects before joining Affluent Medical.
  • Affluent Medical develops innovative, next-generation minimally invasive implants to restore essential physiological functions in these areas.

Astellas to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2™ Trial in Oral Session at The North American Menopause Society 2021 Annual Meeting

Wednesday, September 22, 2021 - 1:00pm

Serious TEAEs occurred in less than 2 percent of patients in the fezolinetant groups and there were no drug-related serious TEAEs.

Key Points: 
  • Serious TEAEs occurred in less than 2 percent of patients in the fezolinetant groups and there were no drug-related serious TEAEs.
  • Detailed safety results will be available following the completion of the fezolinetant Phase 3 program, which will also include the SKYLIGHT 1 and SKYLIGHT 4 studies.
  • The BRIGHT SKY pivotal trials, SKYLIGHT 1 ( NCT04003155 ) and SKYLIGHT 2 ( NCT04003142 ), enrolled 1,028 women with moderate to severe vasomotor symptoms (VMS).
  • SKYLIGHT 4 ( NCT04003389 ), also underway, is a 52-week double-blinded and placebo-controlled study designed to investigate long-term safety of fezolinetant.

RisingStar Announces NFT Drop With The Professor on Crypto.com Platform on Sept. 23

Tuesday, September 21, 2021 - 1:54pm

The Professor approached RisingStar to create an NFT series with Crypto.com.

Key Points: 
  • The Professor approached RisingStar to create an NFT series with Crypto.com.
  • RisingStar then took The Professor's holograms and placed him in seven animated worlds rivaling against different pop culture icons.
  • "We're thrilled to work with The Professor on an NFT drop on Crypto.com.
  • We can't wait to connect with millions of global users on Crypto's platform," said Attila Kralik, founder of RisingStar.